ECOG-ACRIN Cancer Research Group: Lung Neoplasms trials

The registry lists 12 Lung Neoplasms studies with ECOG-ACRIN Cancer Research Group as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 3Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerCompletedNCT01824901Phase 1/2Results posted
• Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung CancerCompletedNCT01107626Phase 3Results posted
• BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by SurgeryCompletedNCT00828009Phase 2Results posted
• Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung CancerCompletedNCT00008385Phase 3Results posted
• Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community SettingWithdrawnNCT03804255
• Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by SurgeryWithdrawnNCT02607423Phase 2
• Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib TosylateCompletedNCT01124669
• Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib HydrochlorideCompletedNCT01123460
• Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and PaclitaxelCompletedNCT00900172
• Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without BevacizumabCompletedNCT00898417
• Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung CancerCompletedNCT00897533
• HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598CompletedNCT00896909